In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on PAVmed (PAVM – Research Report), with a price target of $3.00. The company’s shares closed yesterday at $1.37.
According to TipRanks, Vendetti is a 3-star analyst with an average return of 2.2% and a 36.77% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Aethlon Medical, ReShape Lifesciences, and Nephros.
PAVmed has an analyst consensus of Strong Buy, with a price target consensus of $5.67, implying a 313.87% upside from current levels. In a report released yesterday, Lake Street also maintained a Buy rating on the stock with a $5.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on PAVmed’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $189 thousand and a GAAP net loss of $16.87 million. In comparison, last year the company had a GAAP net loss of $9.43 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The company was founded on June 26, 2014 and is headquartered in New York, NY.
Read More on PAVM:
